117. Syringomyelia Clinical trials / Disease details


Clinical trials : 3 Drugs : 5 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000039678
2021-02-012020-11-05Evaluation of Posterior Fossa Decompression (PFD) without or with Cerebellar Tonsil Thermocoagulation (PFDCT) for Arnold-Chiari Malformation Type I with Syringomyelia: a ramdomised controlled trialEvaluation of Posterior Fossa Decompression (PFD) without or with Cerebellar Tonsil Thermocoagulation (PFDCT) for Arnold-Chiari Malformation Type I with Syringomyelia: a ramdomised controlled trial Arnold-Chiari Malformation Type I with SyringomyeliaA Group:Posterior Fossa Decompression;B Group:Posterior Fossa Decompression (PFD) with Cerebellar tonsil Thermocoagulation (PFDCT);Fujian Medical University Union HospitalNULLRecruiting1865BothA Group:70;B Group:70;China
2NCT02807142
(ClinicalTrials.gov)
March 20163/6/2016Efficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic SyringomyeliaEfficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic SyringomyeliaPost-Traumatic SyringomyeliaBiological: NC 1 cell therapyPuerta de Hierro University HospitalNULLCompleted18 Years70 YearsAll6Phase 2NULL
3EUCTR2015-002383-16-ES
(EUCTR)
19/01/201615/10/2015Evaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyeliaEvaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyelia Traumatic spinal cord injury, chronically established, associated with syringomyelia and neurological deficit considered irreversible.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Células mesenquimales troncales adultas autólogas de medula ósea expandidas
Product Code: CME-LEM4
INN or Proposed INN: células mesenquimales troncales adultas autólogas de médula ósea expandidas
Fundación Investigación Biomédica Hospital Universitario Puerta de HierroNULLNot RecruitingFemale: yes
Male: yes
6Phase 2Spain